Latest Breaking News On - Susan pietropaolo - Page 10 : comparemela.com

NeuroTrauma Sciences Neuroactive Compound NTS-105 Decreases Cell Death in Preclinical Model of Traumatic Brain Injury

NeuroTrauma Sciences Neuroactive Compound NTS-105 Decreases Cell Death in Preclinical Model of Traumatic Brain Injury
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesColumbia universitySusan pietropaoloJudith hedstromHolly evartsColumbia nano initiativeEarth instituteNeurotrauma sciencesPrecision medicine initiativeZuckerman mind brain behavior instituteSymposium of the national neurotrauma societyProfessor of biomedical engineering at columbia universityStrategic communicationsData science instituteFu foundation school of engineering

Aptose Appoints Fletcher Payne as Senior Vice President,

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage.

United statesFletcher payneAptose biosciencesSusan pietropaoloUniversity of californiaLifesci advisorsPlexxikon incDynavax technologies corporationAptose biosciences incCorporate communications investor relationsExchange commissionHaas school of businessRinat neuroscience corporationSenior vice presidentChief financial officerChief executive

NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference

/PRNewswire/ NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to.

District of columbiaUnited statesTomj parrySusan pietropaoloNeurotrauma sciencesChief science officerAnnual traumatic brain injury conferenceTrauma sciencesNeurotrauma sciences llc

CORRECTION -- Aptose Presents Highlights from Corporate

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results .

United statesAptose biosciencesSusan pietropaoloBrian drukerBrian andrew jonasUniversity of californiaLifesci advisorsUniversity of texas md anderson cancer centerCancer centerAptose biosciences incCorporate communications investor relationsExchange commissionOregon health science universityNew complete remissionLuxeptinib demonstrates encouragingOregon health

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAptose biosciencesSusan pietropaoloBrian drukerBrian andrew jonasUniversity of californiaLifesci advisorsUniversity of texas md anderson cancer centerCancer centerAptose biosciences incCorporate communications investor relationsExchange commissionOregon health science universityWall streetNew complete remissionLuxeptinib demonstrates encouraging